Publications by authors named "Nizar M Tannir"

100Publications

The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results.

Cancer J 2020 Sep/Oct;26(5):419-431

From the Division of Cancer Medicine, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000471DOI Listing
September 2020

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye.

Mol Cell Oncol 2020 23;7(5):1777060. Epub 2020 Jun 23.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2020.1777060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469578PMC
June 2020

Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.

BJU Int 2020 Jul 4. Epub 2020 Jul 4.

Departments of , Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15160DOI Listing
July 2020

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Cancer 2020 Sep 9;126(17):3950-3960. Epub 2020 Jun 9.

Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32991DOI Listing
September 2020

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.

Cancer Treat Res Commun 2020 Jan 3;23:100166. Epub 2020 Jan 3.

Department of Genitourinary Medical Oncology, Unit 1374, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030-3721, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2020.100166DOI Listing
January 2020

Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).

Abdom Radiol (NY) 2020 06;45(6):1872-1882

Department of Abdominal Imaging, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02354-zDOI Listing
June 2020

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 12 6;17(6):425-435.e4. Epub 2019 Feb 6.

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518515PMC
December 2019

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 12 23;17(6):451-456. Epub 2019 Jul 23.

Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.07.003DOI Listing
December 2019

Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.

Curr Opin Urol 2019 09;29(5):521-525

Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000661DOI Listing
September 2019

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Cancer Cell 2019 02;35(2):204-220.e9

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.01.006DOI Listing
February 2019

Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Cancer Treat Rev 2018 Nov 20;70:127-137. Epub 2018 Jul 20.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.07.009DOI Listing
November 2018

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2018 06 11;36(16):1588-1593. Epub 2018 Apr 11.

Eric Jonasch, Rebecca S. Slack, Summer Stovall, Donna Juarez, Troy R. Gilchrist, Lisa Pruitt, and Nizar M. Tannir, The University of Texas MD Anderson Cancer Center; Elshad Hasanov, The University of Texas Health Science Center, Houston, TX; Daniel M. Geynisman and Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; W. Kimryn Rathmell, Vanderbilt Ingram Cancer Center, Nashville, TN; and Moshe C. Ornstein and Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.1485
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.1485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804828PMC
June 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Oncologist 2018 05 27;23(5):540-555. Epub 2018 Feb 27.

Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947457PMC
May 2018

A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.

Clin Cancer Res 2018 05 12;24(9):2044-2049. Epub 2018 Feb 12.

Center for Precision Environmental Health, Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-3296DOI Listing
May 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804841PMC
March 2018

Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control.

J Bone Joint Surg Am 2017 Nov;99(22):1916-1926

1Department of Radiology, Baylor College of Medicine, Houston, Texas 2Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, Texas 3Departments of Interventional Radiology (K.A., S.Y.H., S.H.S., and A.L.T.), Genitourinary Medical Oncology (N.M.T.), and Orthopaedic Oncology (V.O.L.), University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2106/JBJS.16.01182DOI Listing
November 2017

Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.

AJR Am J Roentgenol 2017 Dec 24;209(6):1278-1284. Epub 2017 Oct 24.

1 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1473, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.17.18018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722466PMC
December 2017

Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.

Carcinogenesis 2017 10;38(11):1129-1135

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/carcin/article/38/11/1129/4083558
Publisher Site
http://dx.doi.org/10.1093/carcin/bgx083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862287PMC
October 2017

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Clin Genitourin Cancer 2017 Aug 10. Epub 2017 Aug 10.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809227PMC
August 2017

Editorial Comment.

Urology 2017 11 1;109:132. Epub 2017 Sep 1.

The University of Texas, MD Anderson Cancer Center, Austin, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2017.06.049DOI Listing
November 2017

Recommendations for the Management of Rare Kidney Cancers.

Eur Urol 2017 12 16;72(6):974-983. Epub 2017 Jul 16.

Division of Surgical Oncology, Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.06.040DOI Listing
December 2017

Renal Medullary Carcinoma: Establishing Standards in Practice.

J Oncol Pract 2017 07;13(7):414-421

Vanderbilt University Medical Center, Nashville; St Jude Children's Research Hospital, Memphis, TN; University of Texas MD Anderson Cancer Center; Baylor College of Medicine, Houston, TX; American University of Beirut Medical Center, Beirut, Lebanon; Université Paris-Est Créteil, Créteil; Institut Curie; University Pierre and Marie Curie, Paris, France; University of North Carolina at Chapel Hill, Chapel Hill, NC; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; Johns Hopkins University, Baltimore, MD; Memorial Sloan Kettering Cancer Center, New York, NY; and University Hospitals Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.020909DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508447PMC
July 2017

Papillary Renal Cell Carcinoma: A Family Portrait.

Eur Urol 2018 01 19;73(1):79-80. Epub 2017 Jun 19.

Department of Medical Oncology, Pitié-Salpêtrière Hospital, AP-HP, University Pierre and Marie Curie, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.06.004DOI Listing
January 2018

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.

Clin Adv Hematol Oncol 2017 May;15(5):409-418

University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
May 2017

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Curr Oncol Rep 2017 Feb;19(2):14

Departments of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Medical School Hannover (MHH), OE6860 Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0566-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331092PMC
February 2017

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Clin Genitourin Cancer 2017 06 18;15(3):363-370. Epub 2017 Jan 18.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.01.010DOI Listing
June 2017

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.

Oncotarget 2017 Jun;8(26):42149-42158

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522056PMC
June 2017

Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?

Eur Urol 2017 03 2;71(3):415-416. Epub 2016 Nov 2.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.10.034DOI Listing
March 2017

Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.

Clin Genitourin Cancer 2017 04 22;15(2):e205-e208. Epub 2016 Jul 22.

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.07.016DOI Listing
April 2017

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.

J Immunother Cancer 2016 21;4:36. Epub 2016 Jun 21.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1374, 1155 Pressler Street, Houston, TX 77030-3721 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0139-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915058PMC
June 2016

Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials.

Int J Radiat Oncol Biol Phys 2016 08 25;95(5):1405-1413. Epub 2016 Mar 25.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2016.03.022DOI Listing
August 2016

Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support.

Psychooncology 2017 09 3;26(9):1361-1368. Epub 2016 May 3.

Department of Palliative, Rehabilitation & Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.4148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094904PMC
September 2017

Personalised cancer care: promises and challenges of targeted therapy.

J R Soc Med 2016 Mar 1;109(3):98-105. Epub 2016 Mar 1.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0141076816631154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794967PMC
March 2016

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Oncologist 2015 Oct 25;20(10):1140-8. Epub 2015 Aug 25.

Division of Cancer Medicine, Department of Genitourinary Medical Oncology, Department of Cardiology, and Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA; Amgen, Inc., San Francisco, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591942PMC
October 2015

Management of Clinical Stage I Testicular Cancer: How Should We Define Success?

J Clin Oncol 2015 Jul 1;33(20):2321-2. Epub 2015 Jun 1.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/20/2321.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.60.8885
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.60.8885DOI Listing
July 2015

Outcomes for Spine Stereotactic Body Radiation Therapy and an Analysis of Predictors of Local Recurrence.

Int J Radiat Oncol Biol Phys 2015 Aug 4;92(5):1016-1026. Epub 2015 Apr 4.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.03.037DOI Listing
August 2015

High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue: A Preliminary Report.

Integr Cancer Ther 2015 Sep 14;14(5):419-27. Epub 2015 Apr 14.

Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1534735415580676DOI Listing
September 2015